Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Curran Simpson

Curran Simpson

Chief executive, Regenxbio

Appears in 1 story

Notable Quotes

Simpson told investors the data 'gives families a real second option,' according to the May 14, 2026, STAT News report.

Stories

Gene therapy options for Duchenne muscular dystrophy

New Capabilities

Leading FDA submission for RGX-202

For three years, Sarepta Therapeutics has been the only company in the world selling a gene therapy for Duchenne muscular dystrophy. Regenxbio's trial result on May 14, 2026, sets up a second contender for U.S. Food and Drug Administration (FDA) approval.

Updated 3 hours ago